Vytrus Biotech (FRA:V5P) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:V5P Vytrus Biotech SA FRA:V5P
66 GF Score
Price €16.70
GF Value €5.29
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Vytrus Biotech Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Vytrus Biotech Quality Rank Related Terms

FRA:V5P
66GF Score
Vytrus Biotech SA FRA:V5P
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vytrus Biotech (FRA:V5P) Overvalued in 2026?

Based on GuruFocus' analysis, Vytrus Biotech stock appears to be overvalued. The current stock price of €16.70 is trading 215.7% above its estimated GF Value™ of €5.29. GuruFocus considers Vytrus Biotech to be Significantly Overvalued.

Key valuation signals for FRA:V5P:

  • Quality Rank:
  • GF Value™: €5.29 vs. price of €16.70 (215.7% above fair value)
  • GF Score™: 66/100 with 2 warning signs

No single metric tells the full story. See the FRA:V5P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vytrus Biotech Business Description

Other Exchanges VYT:Spain
Address Sant Gaieta 121, 2nd Floor, Terrassa, Barcelona, ESP, 08221
Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.
66GF Score

Get the complete analysis for FRA:V5P

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.70
Price
€5.29
GF Value